MCID: EYL001
MIFTS: 28

Eyelid Neoplasm malady

Categories: Cancer diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Eyelid Neoplasm

Aliases & Descriptions for Eyelid Neoplasm:

Name: Eyelid Neoplasm 12 14
Eyelid Carcinoma 12 14 69
Eyelid Neoplasms 42 69
Carcinoma of the Eyelid 12
Tumor of the Eyelid 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2173 DOID:6425
MeSH 42 D005142
NCIt 47 C3031 C6078
SNOMED-CT 64 278697001

Summaries for Eyelid Neoplasm

MalaCards based summary : Eyelid Neoplasm, also known as eyelid carcinoma, is related to mucoepidermoid thyroid carcinoma and iritis. An important gene associated with Eyelid Neoplasm is FEZF1 (FEZ Family Zinc Finger 1). The drugs Imiquimod and Loteprednol have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotype is cellular.

Related Diseases for Eyelid Neoplasm

Diseases related to Eyelid Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 mucoepidermoid thyroid carcinoma 10.2 FEZF1 FEZF2
2 iritis 10.2 FEZF1 FEZF2
3 bile duct carcinoma 10.2 FEZF1 FEZF2
4 eosinophilia-myalgia syndrome 10.2 FEZF1 FEZF2
5 hepatic angiomyolipoma 10.1 FEZF1 FEZF2
6 basal cell carcinoma 10.1
7 merkel cell carcinoma 10.1
8 strabismus 10.0 KITLG MUC2
9 cervix endometriosis 10.0 KRT20 MUC2
10 trophoblastic neoplasm 9.9 KRT20 MUC2
11 neurofibrosarcoma 9.9 KRT20 MUC2
12 pelvic inflammatory disease 9.9 KRT20 MUC2
13 anemia of prematurity 9.9 KRT20 MUC2
14 appendix mucinous cystadenocarcinoma 9.9 KRT20 MUC2
15 papillary adenofibroma 9.9 KRT20 MUC2
16 sagittal sinus thrombosis 9.9 KRT20 MUC2
17 tabes dorsalis 9.9 KRT20 MUC2
18 pacinian tumor 9.9 KRT20 MUC2
19 gallbladder signet ring cell adenocarcinoma 9.9 KRT20 MUC2
20 adenoiditis 9.9
21 prostate stromal sarcoma 9.9 KRT20 MUC2
22 lung clear cell carcinoma 9.9 KRT20 MUC2
23 small intestine carcinoid neuroendocrine tumor 9.9 KRT20 MUC2
24 neuroretinitis 9.9 KRT20 MUC2
25 placental site trophoblastic tumor 9.9 KRT20 MUC2
26 acute stress disorder 9.9 KRT20 MUC2
27 acute retinal necrosis syndrome 9.9 KRT20 MUC2
28 allergic contact dermatitis 9.9 KRT20 MUC2
29 struma ovarii 9.9 KRT20 MUC2
30 intestinal benign neoplasm 9.9 KRT20 MUC2
31 advanced sleep phase syndrome 9.9 KRT20 MUC2
32 pituitary carcinoma 9.8 KRT20 MUC2
33 odontotrichoungual-digital-palmar syndrome 9.8 KRT20 MUC2
34 oral squamous cell carcinoma 9.8 KRT20 MUC2
35 malignant pleural solitary fibrous tumor 9.8 KRT20 MUC2
36 spinal muscular atrophy with progressive myoclonic epilepsy 9.8 KRT20 MUC2
37 gastroesophageal junction adenocarcinoma 9.7 KRT20 MUC2
38 papilloma 9.6
39 granular cell tumor 9.6
40 verrucous carcinoma 9.6
41 muir-torre syndrome 9.6
42 lymphoma 9.5
43 melanoma 9.5
44 ascending colon cancer 9.2 FEZF1 FEZF2 KITLG KRT20 MFGE8 MUC2

Graphical network of the top 20 diseases related to Eyelid Neoplasm:



Diseases related to Eyelid Neoplasm

Symptoms & Phenotypes for Eyelid Neoplasm

MGI Mouse Phenotypes related to Eyelid Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.02 FEZF1 FEZF2 KITLG MFGE8 MUC2

Drugs & Therapeutics for Eyelid Neoplasm

Drugs for Eyelid Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
2
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
3
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
4 Adjuvants, Immunologic Phase 4
5 Interferon Inducers Phase 4
6 interferons Phase 4
7 Anti-Allergic Agents Phase 4
8 Anti-Bacterial Agents Phase 4,Early Phase 1
9 Anti-Infective Agents Phase 4,Early Phase 1
10
Bimatoprost Approved, Investigational Phase 3 155206-00-1 5311027
11
Fluorouracil Approved Phase 3,Early Phase 1 51-21-8 3385
12
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
13 Antihypertensive Agents Phase 3
14 Pharmaceutical Solutions Phase 3,Early Phase 1
15 Anti-Inflammatory Agents Phase 3
16 Antimetabolites Phase 3,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Early Phase 1
18 glucocorticoids Phase 3
19 Hormone Antagonists Phase 3
20 Hormones Phase 3
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
22 Immunosuppressive Agents Phase 3,Early Phase 1
23 triamcinolone acetonide Phase 3
24 Triamcinolone diacetate Phase 3
25 Triamcinolone hexacetonide Phase 3
26
Acetylcholine Approved Phase 2 51-84-3 187
27
Technetium tc 99m sulfur colloid Approved Phase 2
28
Carmustine Approved Phase 1, Phase 2 154-93-8 2578
29 abobotulinumtoxinA Phase 2
30 Botulinum Toxins Phase 2
31 Botulinum Toxins, Type A Phase 2
32 Cholinergic Agents Phase 2
33 incobotulinumtoxinA Phase 2
34 Neuromuscular Agents Phase 2
35 Neurotransmitter Agents Phase 2
36 onabotulinumtoxinA Phase 2
37 Peripheral Nervous System Agents Phase 2
38 Anesthetics Phase 2
39 Radiopharmaceuticals Phase 2
40 Alkylating Agents Phase 1, Phase 2
41 Antineoplastic Agents, Alkylating Phase 1, Phase 2
42 O(6)-benzylguanine Phase 1, Phase 2
43
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
44
Benzocaine Approved 1994-09-7, 94-09-7 2337
45
Desflurane Approved 57041-67-5 42113
46
Isoflurane Approved, Vet_approved 26675-46-7 3763
47
Remifentanil Approved 132875-61-7 60815
48
Ephedrine Approved 299-42-3 9294
49
Procaine Approved, Investigational, Vet_approved 59-46-1 4914
50
Pseudoephedrine Approved 90-82-4 7028

Interventional clinical trials:

(show all 27)
id Name Status NCT ID Phase
1 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4
2 Pediatric Zylet Safety and Efficacy Study Completed NCT00420628 Phase 4
3 PMCF-study Using Novosyn® Quick Suture Material in Ophthalmic Surgery Withdrawn NCT02761083 Phase 4
4 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
5 Study of Bimatoprost Gel on Eyelash Growth Completed NCT01200251 Phase 3
6 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Completed NCT01202747 Phase 2, Phase 3
7 Chalazia Treatment Study Recruiting NCT02025023 Phase 3
8 Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora Completed NCT01282541 Phase 2
9 Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion Completed NCT02338648 Phase 2
10 Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid Recruiting NCT00832429 Phase 2
11 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma Active, not recruiting NCT00961220 Phase 1, Phase 2
12 Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma Active, not recruiting NCT00386906 Phase 1
13 External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note Completed NCT01274689
14 Helicobacter Pylori and Dry Eye Completed NCT00083291
15 Chalazion Conservative Treatment Trial Completed NCT01230593
16 Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients Completed NCT00478582
17 ONSD According to the Position During Laparoscopy Completed NCT01937104
18 Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS) Completed NCT00610402
19 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye Completed NCT00832130
20 Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa Recruiting NCT02386774
21 Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma Active, not recruiting NCT02039895
22 Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma Active, not recruiting NCT02825511
23 Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Enrolling by invitation NCT01854112
24 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts Not yet recruiting NCT02705352 Early Phase 1
25 Tegaderm and Visual Evoked Potentials Terminated NCT02105337
26 Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants Withdrawn NCT00999557
27 Intralesional Tetracycline Injection in the Treatment of Chalazia Withdrawn NCT01763437 Early Phase 1

Search NIH Clinical Center for Eyelid Neoplasm

Cochrane evidence based reviews: eyelid neoplasms

Genetic Tests for Eyelid Neoplasm

Anatomical Context for Eyelid Neoplasm

MalaCards organs/tissues related to Eyelid Neoplasm:

39
Eye

Publications for Eyelid Neoplasm

Articles related to Eyelid Neoplasm:

id Title Authors Year
1
"Pseudo-pseudochalazion": giant chalazion mimicking eyelid neoplasm. ( 16234710 )
2005
2
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. ( 16142387 )
2005

Variations for Eyelid Neoplasm

Expression for Eyelid Neoplasm

Search GEO for disease gene expression data for Eyelid Neoplasm.

Pathways for Eyelid Neoplasm

GO Terms for Eyelid Neoplasm

Biological processes related to Eyelid Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of neuron differentiation GO:0045666 9.26 FEZF1 FEZF2
2 forebrain development GO:0030900 9.16 FEZF1 FEZF2
3 telencephalon development GO:0021537 8.96 FEZF1 FEZF2
4 forebrain anterior/posterior pattern specification GO:0021797 8.62 FEZF1 FEZF2

Sources for Eyelid Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....